Bibliographic Details
| Title: |
Meeting Report: Controlled Human Influenza Virus Infection Model Studies: Current Status and Future Directions for Innovation. |
| Authors: |
Lane, M. Chelsea1 (AUTHOR), Luke, Catherine J.1 (AUTHOR), Bresee, Joseph2 (AUTHOR), Dugan, Vivien G.3 (AUTHOR), Post, Diane J.1 (AUTHOR), Schafer, Julie4 (AUTHOR), Roberts, Paul C.1 (AUTHOR), Wentworth, David E.3 (AUTHOR), Ison, Michael G.1 (AUTHOR) michael.ison@nih.gov |
| Source: |
Influenza & Other Respiratory Viruses. Oct2024, Vol. 18 Issue 10, p1-9. 9p. |
| Subject Terms: |
*INFLUENZA vaccines, *VIRUS diseases, *VACCINE development, *COMMUNICABLE diseases, *INFLUENZA viruses |
| Abstract: |
On November 13–14, 2023, the National Institute of Allergy and Infectious Diseases (NIAID) in partnership with the Task Force for Global Health, Flu Lab, the Canadian Institutes of Health Research, and the Centers for Disease Control and Prevention convened a meeting on controlled human influenza virus infection model (CHIVIM) studies to review the current research landscape of CHIVIM studies and to generate actionable next steps. Presentations and panel discussions highlighted CHIVIM use cases, regulatory and ethical considerations, innovations, networks and standardization, and the utility of using CHIVIM in vaccine development. This report summarizes the presentations, discussions, key takeaways, and future directions for innovations in CHIVIMs. Experts agreed that CHIVIM studies can be valuable for the study of influenza infection, immune response, and transmission. Furthermore, they may have utility in the development of vaccines and other medical countermeasures; however, the use of CHIVIMs to de‐risk clinical development of investigational vaccines should employ a cautious approach. Endpoints in CHIVIM studies should be tailored to the specific use case. CHIVIM studies can provide useful supporting data for vaccine licensure but are not required and do not obviate the need for the conduct of field efficacy trials. Future directions in this field include the continued expansion of capacity to conduct CHIVIM studies, development of a broad panel of challenge viruses and assay reagents and standards that can be shared, streamlining of manufacturing processes, the exploration of targeted delivery of virus to the lower respiratory tract, efforts to more closely replicate natural influenza disease in CHIVIM, alignment on a definition of breadth to facilitate development of more broadly protective/universal vaccine approaches, and continued collaboration between stakeholders. [ABSTRACT FROM AUTHOR] |
|
Copyright of Influenza & Other Respiratory Viruses is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
|
Full text is not displayed to guests. |
Login for full access.
|
